Antiarrhythmic drugs vs catheter ablation for treatment of atrial fibrillation in an elderly population: A retrospective analysis of Medicare Advantage enrollees in the United States
Heart Rhythm · 2026
DOI: 10.1016/j.hrthm.2026.02.045 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Heart Rhythm, 2026. Verfasst von Robert N D'Angelo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dartmouth Health, Geisel School of Medicine, Hanover, New Hampshire. Electronic address: rdangelo@hitchcock.org. Hauptthemen laut MEDLINE: Anti-Arrhythmia Agents, Atrial Fibrillation, Catheter Ablation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Johnson & Johnson MedTech, Johnson and Johnson.
Abstract (Originalsprache)
BACKGROUND: Catheter ablation (CA) is a widely used therapy for atrial fibrillation (AF), but limited research compares the effectiveness of CA with antiarrhythmic drugs (AADs) in an elderly population. OBJECTIVE: This study aimed to compare AF recurrence and other clinical outcomes for CA with AADs in an elderly population with drug-refractory AF. METHODS: A large nationally representative sample of elderly patients (aged ≥65 years) was studied using the Optum Clinformatics database from 2016 to 2022. The primary outcome was atrial tachyarrhythmia recurrence. Secondary outcomes included direct current cardioversions, heart failure (HF) hospitalizations, myocardial infarctions, ischemic strokes, and death. Propensity score matching was used to balance cohorts. RESULTS: 13,311 patients were identified, with 7230 in the AAD cohort and 6081 in the CA cohort. Patients who underwent CA were 24% less likely to experience recurrence compared with those treated with AADs (hazard ratio [HR] 0.76; 95% confidence interval [CI] 0.65-0.89). The risk of direct current cardioversion (HR 0.74; 95% CI 0.60-0.91), HF hospitalization (HR 0.63; 95% CI 0.45-0.90), and ischemic stroke (HR 0.45; 95% CI 0.28-0.72) was significantly reduced, without differences in death or myocardial infarction. The rate of complications was 5.9% in the CA cohort, whereas adverse events were frequent in the AAD cohort (45.4%). CONCLUSION: CA treatment was associated with a lower risk of atrial tachyarrhythmia, cardioversion, HF hospitalization, and ischemic stroke than AADs. AADs were poorly tolerated in this cohort, and complication rates from CA were similar to those of younger groups. Favorable safety and efficacy support consideration of CA in elderly patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dartmouth Health, Geisel School of Medicine, Hanover, New Hampshire. Electronic address: rdangelo@hitchcock.org.
- MedTech Epidemiology & Real-World Data Science, Johnson & Johnson, New Brunswick, New Jersey.
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
- Johnson & Johnson MedTech, Health Economics and Market Access, Irvine, California.
Förderung
- Johnson & Johnson MedTech
- Johnson and Johnson
Zitieren
APA
D'Angelo, R. N., Rong, Y., Khanna, R., Locke, A., Iglesias, M., d'Avila, A., & Zimetbaum, P. J. (2026). Antiarrhythmic drugs vs catheter ablation for treatment of atrial fibrillation in an elderly population: A retrospective analysis of Medicare Advantage enrollees in the United States. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2026.02.045
Vancouver
D'Angelo RN, Rong Y, Khanna R, Locke A, Iglesias M, d'Avila A, et al. Antiarrhythmic drugs vs catheter ablation for treatment of atrial fibrillation in an elderly population: A retrospective analysis of Medicare Advantage enrollees in the United States. Heart Rhythm. 2026. doi:10.1016/j.hrthm.2026.02.045
BibTeX
@article{DAngelo2026,
author = {D'Angelo, Robert N and Rong, Yiran and Khanna, Rahul and Locke, Andrew and Iglesias, Maximiliano and d'Avila, Andre and Zimetbaum, Peter J},
title = {Antiarrhythmic drugs vs catheter ablation for treatment of atrial fibrillation in an elderly population: A retrospective analysis of Medicare Advantage enrollees in the United States},
journal = {Heart Rhythm},
year = {2026},
doi = {10.1016/j.hrthm.2026.02.045}
}
EUVIMED